Group items tagged

The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for cross-site coordination and communication. Collaborative studies are appropriate to address research projects that go beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and contributions.?Specifically, the purpose of this funding opportunity announcement (FOA) is to support collaborative R01 projects from multidisciplinary teams that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our understanding of the complex etiology of severe mental disorders. Applicants wishing to submit individual l projects should apply to the companion FOA (link).

 The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD.  The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD.  However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains.  The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members.  Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC.  Multi-site clinical trials will not be considered responsive to this FOA.

The goal of this FOA is to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimer's disease (AD), in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. The causal linkage of AD-associated genetic variants identified in genome-wide association studies and genome sequencing studies to molecular and biological cell phenotypes in human neural cells is expected to give greater insight into molecular targets contributing to the etiology of AD. Studies of human genetics in human cells are essential to understanding the etiology of AD.

Epidemiological studies have shown that psychiatric disorders, constitute a significant public health burden across diverse populations worldwide. These mental disorders are characterized by marked genetic heterogeneity, with both common and rare variation contributing to the complex phenotypic outcomes. For reasons such as population homogeneity and ease of ascertainment, most genome-wide genetic studies to date have mainly focused on cohorts of European-ancestry, however, no single population is sufficient to fully uncover the variants underlying neuropsychiatric diseases in all populations. The absence of diverse ancestries in genome-wide association studies has therefore negatively impacted their ability to illuminate the full genetic architecture of complex neuropsychiatric traits. Populations with different ancestral origins vary in terms of allele frequencies, biological adaptations, and other properties that affect the detectability and importance of risk variants. Lack of ancestrally diverse genome-wide data can lead to the misidentification of causal variants due to cryptic population stratification or simply overlooking a causal variant altogether, since rare variants are likely to be more recent in origin and more geographically localized.

This notice announces the opportunity to apply for funding under the Advances in Integrating Genetics into Clinical Care (AIGCC) program. The purpose of this program is to serve as a national resource on the use of genetic and genomic information in clinical practice for genetic service providers, primary and specialty health care providers, and families. The program will accomplish this by implementing the priorities below.

The USGS is offering a funding opportunity to a CESU partner for research on ⿿Characterizing Hybridization of the Pallid Sturgeon and Evaluating Analyses to Improve Species Identification and Assess the Threat of Introgression.⿝ Considerable uncertainty exists regarding the nature, frequency and extent of hybridization between the endangered pallid sturgeon and the common shovelnose sturgeon throughout its range. Resolving this uncertainty is crucial to developing management strategies to recover endangered sturgeon and to prioritize management actions in the large river ecosystems where they reside. Current genetic markers and analyses are insufficient to adequately characterize hybridization between these species and research is needed to identify pathways forward to rapidly develop cost-effective genetic tools.

The USGS is offering a funding opportunity to a CESU partner for research on ⿿Characterizing Hybridization of the Pallid Sturgeon and Evaluating Analyses to Improve Species Identification and Assess the Threat of Introgression.⿝ Considerable uncertainty exists regarding the nature, frequency and extent of hybridization between the endangered pallid sturgeon and the common shovelnose sturgeon throughout its range. Resolving this uncertainty is crucial to developing management strategies to recover endangered sturgeon and to prioritize management actions in the large river ecosystems where they reside. Current genetic markers and analyses are insufficient to adequately characterize hybridization between these species and research is needed to identify pathways forward to rapidly develop cost-effective genetic tools.

Through this Funding Opportunity Announcement (FOA), the National Institute of Mental Health (NIMH) seeks applications to develop, sustain, enhance, and enrich a centralized national biorepository for genetic studies of psychiatric disorders for facilitation and acceleration of the scientific understanding of the genetic risk architecture underlying mental disorders. This effort is expected to involve a functionally integrated, multi-disciplinary team that will provide for open sharing of biosamples and data resources through a single, centralized, national resource to advance basic and translational research in the genetics of mental disorders.

The goal of this FOA is to establish functional genotype-phenotype relationships of genes known to cause Alzheimer's disease (AD), genes or genetic variants suspected of altering the risk of AD, and genetic and biological modifiers that contribute to the disease process in neural cells using human pluripotent stem cells (hPSC) and genome editing approaches. Determining the function of AD candidate risk genes and genetic variants, identified in GWAS and other studies, in hPSC derived human neurons and glial cells is expected to identify new gene or cellular networks and molecular targets underlying the etiology of AD.

The Jerome Lejeune Foundation is the world's oldest and largest private funder of research into treatments for intellectual disabilities of genetic origin, especially, but not limited to, Down syndrome. The Foundation's specific research interest is to discover a means of  treating genetic intellectual disabilities in order to improve the memory, speech, and cognition of patients. Researchers who are working in basic or applied science and who have genetic intellectual disabilities (Down syndrome, Fragile X syndrome, Cri-du-Chat syndrome, rare chromosomal anomalies, Rett syndrome, Williams Beuren, Willi Prader, Angelman…) as their therapeutic target  are invited to submit proposals for funding assistance from the Foundation.

The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven research to discover human biomarkers in Parkinsons disease and other Parkinsonian syndromes, as a component of the NINDS Parkinsons Disease Biomarkers Program (PDBP). This FOA encourages biomarkers discovery projects in 1) genetically causal Parkinson's disease, especially for particular sub-types of Parkinson's Disease (PD), including genetic cohorts, biologically defined cohorts of idiopathic PD, or ethnic subgroups of idiopathic PD; 2) The differentiation of synucleinopathies (such as PD and Multiple System Atrophy (MSA) from tauopathies (such asProgressive Supranuclear Palsy and Corticobasal degeneration); or 3) to improve diagnostic differentiation between idiopathic/subtypes of PD and these disorders, as well as from Essential tremor. In order to further advance research in this area, broad sharing of biospecimens and associated data is a critical feature of the PDBP generally and of this FOA specifically.A timeline including milestones, which will be used to evaluate the application not only in peer review but also in consideration of the awarded project for funding of non-competing award years, is required for all studies.

The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven research to discover human biomarkers in Parkinsons disease and other Parkinsonian syndromes, as a component of the NINDS Parkinsons Disease Biomarkers Program (PDBP). This FOA encourages biomarkers discovery projects in 1) genetically causal Parkinson's disease, especially for particular sub-types of Parkinson's Disease (PD), including genetic cohorts, biologically defined cohorts of idiopathic PD, or ethnic subgroups of idiopathic PD; 2) The differentiation of synucleinopathies (such as PD and Multiple System Atrophy (MSA) from tauopathies (such asProgressive Supranuclear Palsy and Corticobasal degeneration); or 3) to improve diagnostic differentiation between idiopathic/subtypes of PD and these disorders, as well as from Essential tremor. In order to further advance research in this area, broad sharing of biospecimens and associated data is a critical feature of the PDBP generally and of this FOA specifically.A timeline including milestones, which will be used to evaluate the application not only in peer review but also in consideration of the awarded project for funding of non-competing award years, is required for all studies.

This Funding Opportunity Announcement (FOA) issued by the National Institute on Alcoholism and Alcohol Abuse (NIAAA), solicits cooperative agreement (U10) applications focusing on studies that (i) identify genetic variants that affect the susceptibility to develop alcohol dependence in adult and adolescent populations, (ii) determine molecular and functional mechanisms of these variants, (iii) identify and characterize gene x gene and gene x environment interactions leading to alcoholism, (iv) develop and refine phenotypes that will facilitate genetic analysis. (v) perform prospective studies of COGA probands.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation G: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." This Funding Opportunity Announcement (FOA) invites multiple Program Director/Principle Investigator (multi-PD/PI) U01 application for projects aimed at identifying best practices to improve case ascertainment and follow-up care of hereditary cancers, with the goal of improving prevention and detection.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

Genetic and genomic studies have identified genes and gene variants that may impact the fundamental biological mechanisms underpinning substance use disorders (SUDs).  Discovery of these genes/variants, while extremely valuable, is only the first step in understanding the molecular processes that influence SUDs. This Funding Opportunity Announcement (FOA) encourages basic functional genetic and genomic research in two areas:  1. functional validation to determine which candidate genes/variants/epigenetic/non-coding RNA features have an authentic role in SUDs, and 2. detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in SUDs.   

The purpose of this funding opportunity announcement (FOA) is to support innovative investigator-initiated R01 applications using animal models in conjunction with translational/clinical approaches that take advantage of advances in genetics, biochemistry, molecular, and developmental biology to identify the specific genetic, epigenetic, environmental, or gene/environment interactions associated with the susceptibility to and variability of structural birth defects in human populations. Applicants funded through this FOA will join the NICHD Birth Defects Working Group and participate in annual meetings designed to provide a forum to discuss research progress, exchange ideas, share resources, and foster collaborations relevant to the goals of the NIHCD's Birth Defects Initiative.

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to use whole genome sequencing at a Kids First-supported sequencing center to elucidate the genetic contribution to childhood cancers, and to investigate the genetic etiology of structural birth defects.These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.

The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.

This Developmental Research Funding Opportunity intends to support gene function studies in collaboration with the Undiagnosed Diseases Network (UDN) building upon the NIH Intramural Research Programs Undiagnosed Diseases Program (NIH-UDP). Responsive applications will propose to investigate the underlying genetics, biochemistry and/or pathophysiology of newly diagnosed diseases in association with the respective gene variant(s) identified through the UDN. In recent years, gene function studies combined with genetic and genomic analyses and metabolic studies have greatly improved diagnoses of these very rare diseases and advanced scientific knowledge of the underlying pathogenesis. This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact.